Lobe Sciences Ltd. GTSIF focuses on mastering the development of transformational medicines and devices as we build a growing portfolio of intellectual property to support wellness and improve mental health. We focus on clinical development of devices and the use of psychedelic medicines to treat specific indications and brain traumas. We are a dedicated team of pioneering scientists, engineers, and operators committed to the investigation and development of treatments using alternative and nontraditional mechanisms for better health. We are announcing pending patents and preclinical research that includes:
- Psilocybin combined with NAC for the treatment of mTBI and PTSD and other conditions.
- MDMA combined with NAC for the treatment of mTBI and PTSD and other conditions
- Addition of compounds to create memory odor imprint pairing
- Nasal Mist Transducer Device for deilvery of medicines directly to the Olfactory Bulb
- Virtual Reality Headset combined with Nasal Mist Device.
Lobe Sciences Ltd. has launched a preclinical research study using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injury/concussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami's Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.
For more information, get in touch with Lobe Sciences Ltd. GTSIF by contacting us at 604-834-9499.
Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged Goods Products
Released On: 5/19/2021
Lobe Sciences to Present at the Benzinga Global Small Cap Conference
Released On: 5/6/2021
Lobe Sciences Acquires Vitamind Line of Wellness Products
Released On: 5/4/2021
Lobe Sciences Announces Filing of PCT Application
Released On: 4/29/2021
Lobe Sciences Retains Jolt Communications to Increase Investor Awareness
Released On: 2/12/2021
Meet Lobe Sciences A Life Sciences Company Focused on Psychedelic Medicines
Released On: 2/8/2021
Lobe Sciences Announces Pending Patents and Preclinical Research Studies
Released On: 2/5/2021
Lobe Sciences Announces Management Changes and New Director
Released On: 1/18/2021
Lobe Sciences Announces Changes to Board of Directors
Released On: 1/8/2021
Lobe Sciences Announces Jonathan Gilbert Appointed Executive Chairman of the Board of Directors
Released On: 12/14/2020
Lobe Sciences Announces CAD$23,000,000 Sale of Cowlitz Cannabis Option to Ionic Brands Corp.
Released On: 12/1/2020
Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine
Released On: 11/30/2020